FDA approves Medicines Co's ORBACTIV for use in acute bacterial skin and skin structure infections

Medicines Co:Says that the U.S. Food and Drug Administration has approved ORBACTIV (oritavancin) for injection for the treatment of adults with acute bacterial skin and skin structure infections caused by susceptible designated Gram-positive bacteria including methicillin-resistant Staphylococcus...

Thursday, 7 Aug 2014

Endo International PLC raises FY 2014 guidance

Endo International PLC:Raised FY 2014 revenues to a range from $2.78 -$2.86 bln, an increase versus prior range of $2.72 -$2.80 bln.Raised FY 2014 adjusted diluted EPS to a range from $4.00 to $4.20, an increase versus prior range of $3.80 to $4.00.Expects FY 2014 diluted (GAAP) loss per share to be...

Thursday, 7 Aug 2014

DepoMed Inc raises FY 2014 revenue guidance and reaffirms FY 2014 EPS guidance

DepoMed Inc:Raises FY 2014 total revenue guidance of about $215-$230 mln, which includes non-cash revenues related to the PDL transaction and $15 mln in milestones already received in 2014 from Mallinckrodt.Raises FY 2014 GAAP EPS of about $0.36-$0.51, which includes the non-cash PDL revenues and...

Thursday, 7 Aug 2014

Theravance Inc appoints Michael W. Aguiar as president and chief executive officer

Theravance Inc:Appoints Michael W. Aguiar as President and Chief Executive Officer of the company effective Aug. 15, 2014 and as a member of the Board of Directors effective immediately.

Thursday, 7 Aug 2014

Gujarat Themis Biosyn Ltd announces changes in CEO and President

Gujarat Themis Biosyn Ltd:Says Rajneesh Anand, President & CEO of stepped down with effect from Aug. 07.His services will however be available to Company as a Consultant from the same date.Appoints Tapas Guha as CEO of with effect from Aug. 07.

Wednesday, 6 Aug 2014

Biotec Pharmacon says U.S. Patent Office issues new patent for cancer adjuvant therapy

Biotec Pharmacon ASA:Says the United States Patent Office has issued a new patent for cancer adjuvant therapy.Says the patent US 8,791,252 is for a method of treating a variety of different cancers by administrating a combination of a (1,3) beta-glucan and a complement-activating antibody.Says the...

Wednesday, 6 Aug 2014

Health Canada Approves Celgene Corp 's ABRAXANE Plus Gemcitabine for first-line treatment of patients with metastatic pancreatic cancer

Celgene Corp:Says Health Canada has approved ABRAXANE for Injectable Suspension (paclitaxel powder for injectable suspension) (nanoparticle, albumin-bound [nab] paclitaxel) for first-line treatment of adult patients with metastatic pancreatic cancer.Approval is welcome news for Canadians who are...

Wednesday, 6 Aug 2014

Targacept Inc reaffirms FY 2014 revenue outlook

Targacept Inc:Says it continues to not expect significant operating revenues for FY 2014.

Wednesday, 6 Aug 2014

Lijun International Pharmaceutical (Holding) Co Ltd gives H1 2014 profit guidance

Lijun International Pharmaceutical (Holding) Co Ltd:Says the Group is expected to record an increase in the amount of net profit for H1 2014 as compared to the amount of net profit for H1 2013.Increase in the amount of net profit is primarily attributable to growth of the intravenous infusion...

Wednesday, 6 Aug 2014


  • Sectors
  • Asia
  • U.S.
  • Europe

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.